In the BioHarmony Drug Report Database

"Preview" Icon

Ropivacaine

Naropin, Exparel (ropivacaine) is a small molecule pharmaceutical. Ropivacaine was first approved as Naropin on 1996-09-24. It is used to treat postoperative pain in the USA. It has been approved in Europe to treat acute pain. It is known to target sodium channel protein type 5 subunit alpha. Naropin’s patent is valid until 2026-11-28 (FDA).

 

Trade Name

 

Exparel liposomal
 

Common Name

 

ropivacaine
 

ChEMBL ID

 

CHEMBL1077896
 

Indication

 

acute pain, postoperative pain
 

Drug Class

 

Local anesthetics

Image (chem structure or protein)

Ropivacaine structure rendering